Podcasts about md phd

What if everything you thought you knew about skincare, acne, anti-aging, and hair loss was either outdated (or just plain wrong?)In today's solo-hosted episode of The Fitness Stuff (for Normal People), Tony sits down with Carter Gottlieb (aka Eviba Carter): cosmetic chemist, MD/PhD candidate, Chief Product Officer at HelloSkin, and one of the most respected voices in the skincare science world.This is not your typical skincare episode. Carter brings rare depth and clarity to topics normally clouded by hype, influencer noise, and cosmetic marketing.Together, they explore:The truth about acne: what causes it, why most “quick fixes” make it worse, and what actually worksRetinoids vs. Retinol vs. Adapalene: the gold standards for acne and anti-agingThe real reason Korean and European sunscreens outperform American ones (and how to get them)Hair loss 101: minoxidil, finasteride, microneedling, and what makes hair look thickerWhy your skin is a mirror of internal health, and how lifestyle factors like stress, sleep, and diet matter more than you thinkThe skin barrier, slugging, in-clinic vs. at-home treatments, and what to skip entirelyThe future of skincare technology, and how HelloSkin is pushing it forwardAnd yes, the story behind Carter putting a microchip in his handWhether you're battling acne, trying to keep your skin healthy as you age, or just want to stop wasting money on the wrong products, this episode cuts through the BS and gets straight to what actually works, backed by science, not hype.Carter's Recommendations & WebsiteCarter's Recommended Korean Sunscreen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Legion Athletics⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LABOR DAY SALE!!BOGO 50% off for your first order + 2X points on every order after thatuse code “FSPOD” at checkout⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for Fitness Stuff PREMIUM here!!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ALL of our complete 12-week training programsBonus episodes every FridayJust $5 /monthTimestamps:(2:05) Day-of Acne Fixes(15:18) Skin-care vs. Acne-care(37:00) Skin-care + Anti-aging Essentials(48:00) Korean Sunscreen vs. USA Sunscreen(51:10) Tanning Peptides(01:01:24) Carotenoids Supplements For Skin Glow + UV Protection(01:14:44) Skin Care Routine Fundamentals(01:29:00) Slugging(01:39:30) Rise And Fall of Eviba Skincare(01:53:25) Hair Loss + Thicker Hair Essentials

In this special edition episode, recorded live at the ASCO Annual Meeting, hosts Shikha Jain, MD, and Edward Kim, MD, honor Healio's 2025 Disruptive Innovators for their positive disruption in the field of hematology/oncology, and for pushing the status quo to improve clinical practice.  •    Welcome to the fourth annual Healio Disruptive Innovator Awards in hematology/oncology. 1:00 •    VK Gadi, MD PhD, presents the Health Equity Award. 3:56 •    The Health Equity Award winner, Ana Velázquez Mañana, MD, makes a speech. 6:00 •    Morgan Collier presents the Woman Disruptor of the Year Award. 7:38 •    Betty S. Pace, MD, accepts the Woman Disruptor of the Year Award. 9:19 •    The Social Media Influencer Award, presented by Eleonora Teplinsky, MD. 11:53 •    Amani Jambhekar, MD, also known as @ajvictorymd on Instagram and TikTok, accepts the Social Media Influencer Award. 13:13 •    Brenda M. Nevidjon, MSN, RN, FAAN, presents the Advanced Practice Trailblazer Award. 14:40 •    Ashley Leak Bryant, PhD, RN, OCN, FAAN, delivers her acceptance speech for the Advanced Practice Trailblazer Award. 16:19 •    Kamal Jethwani, MD, MPH, presents the Patient Voice Award. 18:44 •    Founder Kimberly Richardson, MA, accepts the Patient Voice Award for the Black Cancer Collaborative. 20:44 •    Healio's chief content officer, Joan-Marie Stiglich, ELS, presents the NextGen Disruptor Award to Nazli Dizman, MD. 22:22 •    The Clinical Innovation Award goes to UNC Lineberger Comprehensive Cancer Center for their at-home symptom reporting, led by Ethan Basch, MD, MSc. 24:18 •    Hope S. Rugo, MD, wins the Lifetime Disruptor Award. 26:48 •    The Industry Breakthrough Award goes to Breyanzi (lisocabtagene maraleucel, or liso-cel) from Bristol Myers Squibb. 30:57 •    On behalf of Bristol Myers Squibb, Amy Corrao, MSN, NP-C, accepts the Industry Breakthrough Award. 32:33 •    Thanks to all of the winners, nominees and sponsors! 35:39 •    Thanks for listening. 36:21 We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Read the full coverage from Healio's Disruptive Innovators here.

In today's episode, supported by Nuvation Bio, we spoke with Joel Neal, MD, PhD, and Christian Rolfo, MD, PhD, about the FDA approval of taletrectinib (Ibtrozi) for the treatment of patients with locally advanced or metastatic, ROS1-positive non–small cell lung cancer (NSCLC). Dr Neal is a professor of medicine in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Rolfo is the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—James and a professor in the College of Medicine at The Ohio State University in Columbus. In our conversation, Drs Neal and Rolfo discussed the significance of this approval, key data from the pivotal phase 2 TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, and taletrectinib's current role in the NSCLC treatment paradigm.

In today's episode, supported by Boehringer Ingelheim, we spoke with Ticiana Leal, MD, and Misako Nagasaka, MD, PhD, about the FDA approval of zongertinib (Hernexeos) for previously treated patients with HER2 TKD–mutant advanced non–small cell lung cancer (NSCLC). Dr Leal is an associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia; as well as medical director of the Clinical Trials Office and leader of the Lung Cancer Disease Team at the Winship Cancer Institute of Emory University. Dr Nagasaka is an associate professor of medicine in the Division of Hematology and Oncology at the University of California, Irvine (UCI) School of Medicine; as well as a medical oncologist at UCI Health. In our conversation, Drs Leal and Nagasaka discussed the significance of this approval, key efficacy and safety findings from the pivotal phase 1 Beamion LUNG-1 trial (NCT04886804), and where zongertinib currently fits into the NSCLC treatment paradigm.

In today's episode, supported by Autolus, we spoke with Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, about the evolving use of obecabtagene autoleucel (obe-cel; Aucatzyl) in the relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treatment paradigm. Dr Logan is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.  In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL. 

Your hairbrush is collecting more strands than your scalp these days. You've tried the shampoos, thesupplements, the ‘miracle cures'—but nothing works. What if the real solution isn't in a bottle… but inunderstanding why your hair is falling out in the first place? This Hair Loss Awareness Month, we'recutting through the hype and revealing what actually stops shedding and regrows hair—backed byscience. From FDA-approved treatments to nature's hidden remedies this is your guide to taking backyour hair—and your confidence.Special Guest: Dr. Ken Washenik, MD PHD and Chief Medical Officer of Bosley HairRestoration

What if your dinner could work as well as your prescription? In this episode, I'm joined again by Dr. Mary Sco., MD-PhD in Nutrition Sciences, to break down head-to-head comparisons of diet and lifestyle changes versus medications. From cholesterol and blood pressure to migraines, diabetes, and even mental health, we look at the research on when food can match—or even outperform—pharmaceuticals, and when prescriptions are still the best choice. LINKS The Truth Behind Seed Oils with Dr Mary Sco | https://bit.ly/4fIk4Cr  Molly's ‘Beyond LDL' podcast with Dr Lavie | https://bit.ly/4mk3Sd1 Fish Oil: A Master Class with Dr Lavie | https://bit.ly/46X4KzH Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Faculty of Medicine in Osaka, Japan.

In this episode, we speak with Prof. Johannes Gojo, MD, PhD, one of the world's foremost experts in pediatric neuro-oncology. Dr. Gojo shares groundbreaking research into ETMR and ATRT brain tumors, the promise of liquid biopsies, and how international collaboration through CARE for RARE (established by Solving Kids' Cancer) is transforming outcomes for children with rare brain tumors.We also highlight a newly funded research project, supported by multiple organizations including Gold Ribbon Kids, that aims to deliver precision medicine breakthroughs for some of the most aggressive childhood cancers.Topics CoveredWhy ETMR and ATRT are so difficult to treatThe role of liquid biopsies in monitoring and guiding therapyHow CARE for RARE and global consortia accelerate progressThe impact of family-driven advocacy on scientific discoveryThe hope behind newly funded research initiatives

Camidge and Lee discussed Lee's professional journey and personal insights gained from years of working at the intersection of clinical research and patient care. 

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Our guest is a dermatologists who sees patients and does research at Wake Forest University Baptist Medical Center in Winston-Salem, one who is internationally recognized for his work in dermatology, particularly in psoriasis and on how well patients use recommended treatments. If you count publications, our guest may be the most productive researcher at Wake Forest. With over 1,500 Medline-referenced publications, his research spans clinical trials, behavioral economics, and public health policy. Today, we'll dive into the risks and benefits of sun exposure, the amazing landscape of modern psoriasis treatment, and what we've learned about how poorly patients take their medication and whose fault it is. Welcome Dr. Steve Feldman, Professor of Dermatology at Wake Forest University School of Medicine. Learn more about Dr. Feldman's background and research at https://school.wakehealth.edu/faculty/f/steven-r-feldman

  Interviewees: Tom Pisano, MD PhD and Laura Ashley Stein, MD, MS, Ed. Interviewer: Lisa Meeks, PhD, MA Description: In Episode 111, Dr. Lisa Meeks talks with Dr. Tom Pisano (former Penn neurology resident; now neuro-hospital medicine and neuro-immunology fellow) and Dr. Laura Stein (Adult Neurology Program Director at Penn) about building an accessible neurology residency for a physician who uses a wheelchair—and how trust, planning, and culture made it work. Together, they trace Tom's match-day disclosure strategy and “find-your-people” approach, an accessibility walk-through with tape measures and ADA checks, and the practical creativity of equivalent rotations when sites differ in accessibility. They also unpack a real barrier—a security policy that blocked ED entry during stroke alerts—and how reframing access as patient safety moved the system. Listeners will hear candid advice for residents (hold onto your “why,” communicate early, invite teaching adaptations) and for program directors (start with goals, not habits; assume success; apply the same creativity you offer patients to your trainees). This episode accompanies a written case study and a Mini Grand Rounds conversation in Learn at ACGME. Part of the ACGME/DWDI Disability Resource Hub, supported by the Josiah Macy Jr. Foundation Catalyst Award, it's a practical guide for PDs, residents, and anyone committed to equitable clinical training.   Transcript: https://docs.google.com/document/d/1xB_Cp8EiekJ9ExUZLP61EvE-0y4HUv22LuRp0D6uNB0/edit?usp=sharing Key words: Medical education, physical disability, disability research, residency, accommodations, wheelchair, SCI, medical technology, residency, neurology, program director, GME, GME Policy Bio: Laura Stein I have been involved in the Neurology Residency Program since 2018, and Director of the program since 2024. I teach residents on multiple inpatient services as well as in outpatient continuity clinic and stroke clinics. I also lead didactic sessions and workshops for resident onboarding and in our resident lecture series. I am particularly interested in expanding resident exposure to structured experiences in medical education and quality improvement and currently mentor multiple residents per year in medical education and quality improvement projects. In 2020, I was honored to receive the University of Pennsylvania Neurology Residents teaching award. I received my masters in medical education from the University of Pennsylvania in 2018. I have been a member of the American Academy of Neurology (AAN) Residency-In-Training Examination Committee since 2019. I have also been a member of the American Heart Association (AHA) Stroke Professional Education Committee since 2016 and currently serve as the Vice Chair of this committee. Clinically, I function predominantly as a neurohospitalist and attend on the stroke inpatient and consult services, the neurology ward service, and the PPMC consult service. I am dedicated to ensuring delivery of high-quality neurologic care across our system and currently am the physician co-lead for our neurovascular disease team, which spans our six-hospital network, as well as our HUP inpatient neurology unit-based quality improvement team. Tom Pisano I enjoy weekend bike rides with my wife, followed by trying out a new restaurant. When traveling, if possible, I always try to get in some monoskiing or scuba diving. I would also consider myself a (very) mildly competitive board gamer. I will be pursuing a combined neurohospitalist/neuroimmunology fellowship to develop expertise in myelopathies. My research includes brain-computer interfaces, especially of the spinal cord. Producer:  Lisa Meeks Follow Us: X: @DocsWith Instagram: @DocsWithDisabilities Linked In: https://www.linkedin.com/company/docs-with-disabilities-initiative Resources:  Disability Resource Hub: https://dl.acgme.org/pages/disability-resource-hub Case Studies in Disability Resource Hub: https://dl.acgme.org/pages/disability-resource-hub#case_studies UME to GME Toolkit:  https://dl.acgme.org/pages/disability-resource-hub-transitions-toolkit-introduction Policy Toolkit: https://dl.acgme.org/pages/disability-resource-hub-policy-toolkit Disability in Graduate Medical Education Program:  https://www.docswithdisabilities.org/digme   Link to Case Study: Coming Soon!              

In this episode, Raval welcomed David A. Frank, MD, PhD, FACP, who is director of the Division of Hematology and a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center.

In our conversation, Dr García-Carbonero discussed a subgroup analysis from the phase 3 FRESCO-2 trial (NCT04322539), which evaluated fruquintinib (Fruzaqla) in previously treated metastatic CRC (mCRC). She reviewed efficacy outcomes by metastatic site, including liver-only, lung-only, bone, and peritoneal disease. Fruquintinib demonstrated improvements in overall survival and progression-free survival across all subgroups, underscoring its feasibility in later-line settings for patients with mCRC. She also addressed prognostic differences between metastatic sites, noting that all patient groups derived benefit from treatment. Dr García-Carbonero also shared findings from PROMETCO, the first international, prospective, real-world study in mCRC, which is examining real-world outcomes for this patient population. 

You've experienced this before, right? You know you're supposed to do something. You've learned that a good habit is what you need or a bad habit needs to be changed. You know you should spend more time on this and less time on that. You know it'd be good for your emotional health, your body, or your soul. But you don't do it. There's a gap. Dr. Kyra Bobinet, MD-PhD, calls it the “Know-Do” gap. It all stems from work she's done for years studying, researching and trying to make practical information about how your brain works, namely your habenula (huh-BEN-yuh-luh). It's the part of your brain that tracks your failure. It can keep you out of trouble: “Last time you tried between those trees, you fell and almost died. Don't do it. Bad!” But it can also keep you mired in bad habits, indecision, and self-doubt: “Remember when you tried that diet, and you fell off it? What a failure. Don't try losing weight again. You'll never do it! You'll fail again!” Dr. Bobinet has a magic (but, really, not so magic) way to calm down your habenula and self-critic: the iterative mindset, which she details in her book Unstoppable Brain (2024, Forbes Books). You've got to change from focusing on failures and trying to keep adding good habits and removing bad habits the same way … and recognize that every time you hit a bump, it's time for a new iteration. Change things up! What worked to help you last year, last week, yesterday, may not work again. Iterate, iterate … change, change … try, try …  I interview Dr. Bobinet here about all that, plus, especially, her nearly brand-new smartphone app Fresh Tri, which offers a platform to learn about her research and how it applies to your habits and health as well as anonymous community support and tips and ideas to change your thinking when your habenula gets going and you're sure this one's the absolute failure. It's all free content and functionality right now with the possibility that more targeted videos and help might be pay-to-play. But for now … go play with all that's there! So, stop logging failures, start logging iterations … and listen in …

The New Chemist's Podcasting Group — The Path to KOLs: Accelerating First-in-Human in LATAM — Julio G. Martinez-Clark, CEO, bioaccess® w/ Chadwin Hanna, MD-PhD Student (UF) and David Ferguson (Host)---On The Path to KOLs from The New Chemist's Podcasting Group, hosts David Ferguson and Chadwin Hanna explore how Latin America is becoming a strategic engine for high-quality, cost-effective clinical research.Julio G. Martinez-Clark—Ambassador of IAOCR/GCSA Americas and CEO of bioaccess®—breaks down how aligning to global competence standards and smarter site activation can compress timelines for First-in-Human and Early Feasibility Studies without compromising quality. He shares lessons from pioneering trials, practical blueprints for building city-level clinical hubs, and pragmatic guidance for innovators entering LATAM markets. The conversation also touches on sustaining regional infrastructure, cross-border collaboration, and the mindset behind his long-running Global Trial Accelerators™ series.Guest: Julio G. Martinez-Clark, CEO, bioaccess®Hosts: David Ferguson, BS, MS, Pharm.D. Candidate; Chadwin Hanna, MD Candidate & PhD StudentPlease note: The views of this podcast reflect those of my guest(s) and I, and do not constitute medical advice, consultation and suggestions. Please see a board certified and state licensed medical professional.

In this episode, Sam Ashoo, MD interviews Christina Shenvi, MD, PhD, MBA about ways to manage your day and keep distraction at bay.Introduction to Dr. Christina ShenviWhy Focus and Time Management MatterExperiences coaching medical students and professionalsThe importance of managing mind, time, and attentionApplicability to both career and personal lifeFramework for FocusThree-step framework: Prioritize, Strategize, FocusExplanation of prioritizationMapping personal and professional activities to prioritiesDeep Work vs. Shallow WorkDefining deep work and shallow workStrategies for categorizing and scheduling tasksTime-blocking and protecting focus timeOvercoming DistractionThe psychology of distraction and procrastinationThe impact of digital devices and social media on attentionThe variable reward system of social media and its addictive natureStrategies to Improve FocusClearing mental, physical, and digital environmentsThe importance of a distraction-free workspaceSystems for capturing and organizing tasksThe Pomodoro method and using time pressureBuilding a Personal SystemExperimenting with different task management toolsAdapting systems to personal needs and preferencesDaily Practice and Training FocusReviewing and updating task lists dailyChunking email and shallow work to specific timesTraining the brain to focus like a muscleSpecial considerations for people with ADHDResources and ContactDr. Shenvi's website and online course (timeforyourlife.org)Invitation to connect for coaching or further learningFor more about Christina Shenvi : https://timeforyourlife.org/

In our exclusive interview, Dr Blanco discussed the significance of this regulatory milestone for a population that has historically lacked effective medical options. He reviewed the pivotal phase 2b ReNeu clinial trial (NCT03962543)that supported this decision, which enrolled both adult and pediatric patients with nonresectable PNs and evaluated clinical and radiologic response rates. Dr Blanco detailed the study's findings, including overall response rates of 41% and 52% in the adult and pediatric populations, respectively; meaningful reductions in tumor volume; improvements in patient-reported pain and quality of life; and the favorable safety profile characterized primarily by dermatologic and gastrointestinal adverse effects.

In our exclusive interview, Dr Élez discussed recent data comparing nivolumab (Opdivo) monotherapy with nivolumab plus ipilimumab (Yervoy) across multiple lines of therapy in patients with MSI-H mCRC. She detailed efficacy and quality‑of‑life outcomes, noting that the combination appeared to offer enhanced clinical benefit without a negative effect on tolerability. Dr Élez also highlighted the importance of tailoring immunotherapy strategies based on patient characteristics and treatment goals and reflected on the nuances of sequencing single‑agent vs combination checkpoint blockade.

Mauro Zappaterra obtained his MD and PhD from Harvard Medical School. He is board-certified in physical medicine and rehabilitation with a focus on optimizing human performance, increasing awareness and decreasing suffering. He has been practicing mindfulness since 1998, and teaching mindfulness to patients with chronic pain since 2018, and he is the Director of Multidisciplinary Care at Synovation Medical Group.  He has led the Awakening Awareness Program and Inward Inquiry for the Emerging Sciences Foundation which can be found on YouTube.  He has published numerous scientific papers and medical book chapters on the cerebrospinal fluid, disability, and pain management. He has also published "I Am", "All One", and "All Love" which are three books exploring topics of awareness, primarily for kids, but really for people of all ages.  He has also published "Close Your Eyes, What Do You See?" with his son, which is a story about imagination and intention.  And he also published "A is for Awarness: A Consciousness Expanding Alphabet", a new alphabet book.  These can all be found on Amazon. He continues to create programs to help patients with chronic pain and investigate the cerebrospinal fluid and integrate new research to evolve the hypothesis of The Cerebrospinal Fluid and I Am. SHOWNOTES:

Uniting scientists and harnessing the power of the immune system to fight disease is at the heart of the Center for Human Immunobiology (CHI). Stephanie Eisenbarth, MD, PhD, leads the center, and she is also the chief of Allergy and Immunology in the Department of Medicine.   Since this episode was first recorded in fall 2022, Eisenbarth's team has launched a clinical trial to study a new treatment for food allergy. She has also brought together more than 150 trainees and faculty through the CHI. Here, she discusses the variety of immunology research taking place within the center and the continued work to discover and translate innovative science into cures for immune-related diseases. 

In today's episode, we had the pleasure of speaking with Martin F. Dietrich, MD, PhD, about updates and best practices for HER2 and MET immunohistochemistry (IHC) testing for patients with non–small cell lung cancer (NSCLC). Dr Dietrich is a medical oncologist at Cancer Care Centers of Brevard in Rockledge, Florida; as well as an assistant professor of internal medicine at the University of Central Florida in Orlando.  In our exclusive interview, Dr Dietrich discussed the rationale for testing for these mutations in patients with NSCLC, standard practices for implementing these tests in the clinic, and when testing may be appropriate at disease progression. 

Dirk R. J. Kuypers, MD, PhD - Predicting and Achieving Long-Term Graft Survival in Solid Organ Transplant Recipients: On Track or a Challenge Too Far?

About this episodeIn this powerful episode, we dive deep into the heart of one of the world's most prestigious scientific institutions—the Weizmann Institute—and explore how cutting-edge innovation, visionary philanthropy, and unwavering resilience are shaping the future of medicine and humanity. From revolutionary MD-PhD programs redefining medical education, to breakthrough blood cancer detection methods published in Nature, to the relentless spirit of scientists rebuilding amidst adversity—this conversation is a testament to hope, courage, and the pursuit of progress against all odds. Join us as we uncover how the legacy of scientific excellence is being fiercely protected and propelled forward, inviting you to be part of a movement that transcends generations and changes the course of human health forever. About the Weizmann Institute of ScienceThe Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research and graduate institutions. Committed to science for the future of humanity, the scientific community of nearly 5,000 engages in best-in-class exploratory research that leads to breakthrough advances in health and medicine, brain and neural science, environmental sustainability, renewable energy, food security, space exploration, quantum computing, artificial intelligence, and education. The American Committee for the Weizmann Institute of Science shares the Institute's devotion to advancing world-changing science, partnering with generous individuals, foundations, and corporations to help Weizmann scientists answer some of the most difficult questions facing humanity. Learn more at WEIZMANNUSA.ORG. What happened on June 15During the early hours of June 15, the Weizmann campus was devastated by two direct hits from ballistic missiles launched by Iran as part of a broad attack on Israel's civilian infrastructure.Five major research buildings were destroyed or significantly damaged. More than 50 labs have been impacted, many losing years of scientific progress in areas that include cancer, life sciences,  and computer science. 400 international students have been displaced. Early estimates for the total cost of damages range between $300 million and $500 million. (View video footage from Kan News)What now?The Institute and its global community maintain their resolve that the science must go on because it is critical to addressing some of humanity's most pressing and widespread challenges. Currently, they are engaging in a global fundraising effort that is essential to providing immediate relief and propelling their long-term rebuilding plans. With such significant damage, philanthropists have an opportunity to play a greater role in world-changing science than ever before. Now is the time to talk to the American Committee about making a gift to the Emergency and Recovery Fund, and do something bold, great, and lasting. Contact CEO@acwis.org to support the Emergency and Recovery Fund.About this guestDave Doneson has been CEO of the American Committee for the  Weizmann Institute of Science since September 2018. Under Dave's  leadership, the American Committee has significantly expanded its  outreach on behalf of the Institute, advocating for some of the most  innovative, transformational, and essential scientific research in the  world today. Weizmann's generous donors have responded in kind,  increasing their philanthropic support of science for the future of humanity to record levels. Prior to joining the American Committee, Dave was Chief Development  Officer of the American Technion Society (ATS), where he led a team  of more than 30 fundraising professionals focused on frontline  fundraising for the Technion – Israel Institute of Technology. He  previously served as Director of Development for the University of  Michigan Health System, where he managed teams focused on major  gifts fundraising. Dave holds a ... read more at www.9x90.co/Dave-Doneson

In this conversation, I sit down with Nick to unpack the deeper science behind GLP-1s and metabolic health. We explore how compounds like Tirzepatide and GLP-1 agonists go beyond weight loss, influencing everything from cardiovascular elasticity and neuroinflammation to mood, cognition, and gut-brain signaling. We also discuss lesser-known drivers of real change, like adiponectin, MPO, and the surprising effects of statins on inflammation.But the conversation doesn't stop with human health. We dive into the behavioral power of the microbiome, how dogs might reduce childhood allergies, and whether AI can actually translate what your pet is thinking. If you're curious about fat loss, brain health, and the future of metabolic science, this episode offers a perspective you won't find anywhere else.*Chapters:*0:00 – Meet Dr. Nick: From Patient to Pioneer06:50 – The Problem with "Evidence-Based Medicine"10:15 – Why Nick Left the Medical System13:10 – Can YouTube Have a Bigger Impact Than Hospitals?16:30 – What Is Metabolic Health & Why Does It Matter?19:00 – Mental Health, Depression & Metabolism24:15 – Brain Hacks That Actually Work40:00 – Improving Metabolic Flexibility Naturally46:00 – Gut-Brain Connection & Fiber Myths*Nick's Socials + Website*IG: https://www.linkedin.com/in/nicknorwitz/Youtube channel: https://www.youtube.com/channel/UCLTZUJSEulehPtF_ytFiU_AWebsite: https://www.nicknorwitz.com*Kayla's Socials + Website*Instagram: https://www.instagram.com/kaylabarnes/TikTok: https://www.tiktok.com/@femalelongevityTwitter: https://x.com/femalelongevityWebsite: https://www.kaylabarnes.comFollow Her Female Protocol: https://www.protocol.kaylabarnes.comBecome a Member of Kayla's Female Longevity Membership: https://kayla-barnes-lentz.circle.so/checkout/become-a-member

Drs Camidge and Blue discussed Dr Blue's journey into practicing medicine that led him to his current specialty: the management of malignant hematologic conditions.

This week on Careers in Discovery, we're joined by Erica Barnell, Chief Medical Officer and Co-founder of Geneoscopy. Erica shares how Geneoscopy is transforming gastrointestinal health with a platform that uses RNA biomarkers from stool samples to diagnose, monitor, and help prevent colorectal cancer and other GI diseases. She talks about the inspiration behind the company, building a patient-friendly alternative to colonoscopy, and why early detection is key to changing outcomes in colorectal cancer. We also dive into Erica's journey from MD-PhD student to entrepreneur, the challenges of shifting from product development to commercialization, and how she navigates the balance of leadership, family, and growth in a dynamic start-up environment.  

If you've been searching for a roadmap to true physician financial freedom, Dr. Christopher H. Loo, MD-PhD, shares how he quit medicine and built lasting wealth through strategic investing, entrepreneurship, and mindset shifts.In this episode of Permission to Kick Ass, we unpack what it means to escape burnout and reclaim your time, money, and energy outside traditional medical practice. Dr. Loo opens up about his journey from physician to multimillionaire investor, offering real-world advice that speaks directly to those looking for:financial independence for doctorsleaving medicine for entrepreneurshippassive income for physiciansburnout solutions for healthcare professionalsinvestment strategies for doctors

Please visit answersincme.com/860/97851223-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the practical application of immunotherapy-based regimens for the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.

"I have had quite some reactions to the article [on their psychoanalyses]. I was also telling Mauro and my colleagues that out of quite a number of articles I've published on maybe more pressing issues in the field of cancer research, for example, brain tumor research that I've spent quite some time with, I think it's actually the article [on psychoanalysis] that probably prompted the most reactions, at least in my personal surroundings, and the reactions have been overwhelmingly positive. So colleagues are very interested. They often ask questions about psychoanalysis, quite specifically, how it works, how it contributed, and also complemented the article in the sense that it was something that was quite outside of the box, so outside of the typical surgical publication.” - FV   "How can we reach surgeons? How can we make this interesting and attractive for them to even consider? I think most surgeons will be very performance-driven people, and I think that it goes hand in hand that that type of person will seek ways to improve themselves, but probably more in a technical way. Let's say they want to get faster in their operations. They want to get more skillful. They want to do more complicated surgeries. So there's a lot about self improvement in that you exercise until you master something. And I think that analogy with sports was our way of saying, hey, you know, this is actually pretty cool. You can compare yourself to  professional athletes, in terms of self improvement, and this is actually one way you can get there, how you can improve. At the same time, it was also important for us to acknowledge that it's not for everyone so we also mentioned alternatives, of course." - MV   Episode Description: Mauro and Flavio begin by describing the encouragement they received from their father to pursue personal analysis "to explore our unconscious minds for a lighter life and less emotional baggage." They share their psychoanalytic journeys and give examples of how their greater capacity to reflect instead of react has led to improved surgical patient outcomes. They also describe collegial tensions that were more clearly addressed through their ability to authentically know how they felt. They recommend that like elite athletes who have sports psychologists to address obstacles to their performances, so might surgeons appreciate the utility of psychoanalysis and other measures to improve their clinical attunement. Mauro concludes "Everyone has their baggage - don't be afraid to look at it and to understand what's going on. It's worth it."   Our Guests: Flavio Vasella, MD PhD, is a junior attending neurosurgeon at the University Hospital Zurich, with a clinical and research focus on neurosurgical oncology. He earned his PhD in Molecular Life Sciences at the University of Zurich, where his research explored genome editing strategies in primary brain tumors. His primary academic interests include translational and clinical neuro-oncology as well as surgical education.   Mauro Vasella, MD, is a board-certified plastic surgeon with multiple years of clinical experience specializing in reconstructive surgery. He is affiliated with the University Hospital Zurich in Switzerland and the Royal Melbourne Hospital in Australia and has held positions as a fellow and attending surgeon. His practice and research field focuses on regenerative-reconstructive surgery and burn injuries.   Recommended Readings: FV - Paul Kalanithi – When Breath Becomes Air This memoir by a neurosurgeon-turned-patient is a poetic and piercing meditation on mortality, identity, and the transition from doctor to patient. It explores the tension between the analytical and emotional mind (somewhat paralleling the internal work of psychoanalysis) and offers profound insight into the humanity at the core of medical practice. Bill George – True North: Discover Your Authentic Leadership This book presents a leadership philosophy rooted in self-inquiry, values, and life stories. True North emphasizes that effective leadership comes from understanding your life narrative and using that insight to lead with integrity and resilience. True North challenges leaders to cultivate authenticity by exploring their internal landscape. While the book focuses on leadership in a business context, it offers a compelling, practical perspective for medical professionals as well. Atul Gawande – Complications: A Surgeon's Notes on an Imperfect Science Gawande offers a candid look at the uncertainties, dilemmas, and emotional burdens of being a surgeon. His reflection on fallibility and decision-making underlines the importance of non-technical skills and the internal work required to become not just competent, but humanely attuned, in medicine. The impact of nontechnical skills on technical performance in surgery: a systematic review. Hull L, Arora S, Aggarwal R, Darzi A, Vincent C, Sevdalis N. J Am Coll Surg.2012  This systematic review analyzed 28 studies linking surgeons' non-technical skills—such as teamwork, situational awareness, and stress management to actual technical performance in the operating room. It found evidence that effective NTS positively affects outcomes, while fatigue and communication failures contribute to technical errors.   MV - The Art of Loving – Erich Fromm Realizing the simple but somehow not always obvious fact that before being able to truly love someone, one must truly find themselves loveworthy. This implies and demands introspection, as well as forgiveness towards yourself and others. Outliers: The Story of Success – Malcolm Gladwell To master something, one must invest a substantial amount of time and dedication – this is not only true for technical skills, but also non-technical skills. Personal growth is only possible if you invest time, such as undergoing a psychoanalysis or similar. The Checklist Manifesto – Atul Gawande While the checklist itself is very technical, the way it was conceived and its effect was and still is rather non-technical. It is a question of putting your ego aside and truly focusing on areas which you can improve.  

Drs. El-Hayek and Shao talk with EAES President Dr. Nicole Bouvy about surgical training in Europe vs. the US, sustainability in surgery, women in leadership, and sheep.

In this episode of Life Gets MoCrazy, Jamie MoCrazy speaks with Michael A. Jensen, an MD/PhD student at the Mayo Clinic whose life changed in an instant after a cycling accident caused a traumatic brain injury. What followed was a remarkable story of perseverance, intellectual growth, and emotional healing. Michael shares how his recovery deepened his passion for neuroscience and ultimately brought him back to Mayo—this time, as a student and researcher.In this episode, we talk about:How Michael rebuilt his identity after a severe brain injury and returned to Medical School to pursue his PHDThe power of mindset, family support, and structured recovery in long-term healingAsking “why”: integrating personal experience into professional purpose

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YCM865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until July 17, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Improve Detection and Optimize Response in Specialty Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YCM865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until July 17, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Improve Detection and Optimize Response in Specialty Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YCM865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until July 17, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Improve Detection and Optimize Response in Specialty Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YCM865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until July 17, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Improve Detection and Optimize Response in Specialty Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YCM865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until July 17, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Improve Detection and Optimize Response in Specialty Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In our exclusive interview, Drs Leleu and Faiman discussed the unique methods and design of IRAKLIA, key efficacy and safety findings from this trial, and the benefits of using on-body delivery systems to deliver effective therapies to patients in more convenient and patient-centered ways. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Meniscus tears can be confusing. They can occur with trauma or not, they come in a variety of shapes and locations which can influence treatment options and outcomes profoundly, and the right treatment remains a matter of great debate. The literature is likewise confusing, and historically has been heterogeneous. Dr. Benjamin MA, MD, PhD from the famed UCSF joins us to discuss an international multi-society expert panel he took part in to generate consensus statements regarding meniscus tear treatment. The consensus statements give all of us in the Sports Medicine world some guidance and reassurance for our approach to this seemingly simple structure, the meniscus, that, when torn, is full of complexities. 

In today's episode, we had the pleasure of speaking with Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD, about a study they conducted investigating the use of immunohistochemistry (IHC) as a biomarker for early TP53 mutation identification in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Gerber is a member of the faculty in the Department of Medicine at New York University (NYU) Grossman School of Medicine; as well as the chief clinical officer of the NYU Perlmutter Cancer Center. Dr Patel is an associate professor at the University of Massachusetts Chan Medical School; as well as a hematologist and oncologist at the UMass Memorial Medical Center in Worcester.  In our exclusive interview, Drs Gerber and Patel discussed the evaluation of p53 IHC as a surrogate biomarker for TP53-mutant MDS and AML. They shared how the presence of TP53 mutations in these diseases significantly worsens prognosis, necessitating urgent treatment. They also highlighted how IHC results are available within 48 to 72 hours. Gerber and Patel explained this study's design and patient population, as well as how IHC's inverse correlation with overall survival highlights its potential as an early biomarker, though it has lower sensitivity for certain mutations.

Physician entrepreneurship is quickly becoming a path forward for doctors looking to reclaim their time, purpose, and financial stability. In this episode, Dr. Christopher H. Loo, MD-PhD sits down with Dr. Pranay Parikh, MD, a practicing physician, podcast host, and real estate investor who exemplifies how physicians can thrive both inside and outside of clinical practice.Many doctors feel stuck trading time for money or are suffering from burnout in medicine. Whether you're a physician frustrated with rigid hospital systems or simply looking for a new challenge, Dr. Parikh's journey offers real answers. He speaks candidly about the power of launching side hustles for physicians, building passive income for doctors, and how to strategically pivot from doctor to entrepreneur—even with limited time.As co-founder of Ascent Equity and contributor to Passive Income MD, Dr. Parikh has helped thousands of physicians learn how to create financial freedom for physicians through scalable ventures like real estate syndication for doctors. If your search history includes “how do I leave medicine?” or “how can I earn more without more shifts?”, this episode was made for you.

In today's episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.

Turning down that med school acceptance might cost more than you think. Listener “my initials are ARM” got into medical school—cue the confetti—but now that reality's set in, she's not feeling great about her only acceptance. The school is small, expensive, and far from home. Should she go anyway or risk reapplying in hopes of a better fit next year? MD/PhD students Michael Arrington, Shruthi Kondaboina, Jessica Smith, and M1 Maria Schapfel weigh the real costs of walking away from an acceptance, from the red flags admissions committees look for to the gamble of getting in again. They get honest about finances, family, and the very unsexy truth about how much the campus “vibe” actually matters. Plus, what to say if you do it anyway. Bonus: the MD/PhD students dish about why they took that road, while Maria counters with why MD is better for her.

Financial freedom is the dream of many professionals—but few achieve it as strategically and successfully as Dr. Christopher H. Loo, MD-PhD. In this episode, Chris shares his journey from physician to early retiree at 38, diving deep into the mindset and investment tactics that led him there.Along the way, we explore the importance of passive income, building multiple streams of income, and how real estate investing during the 2008 crash set Chris on a path to lasting wealth. He also discusses the power of digital entrepreneurship, creating a personal brand, and how index funds investing can create long-term security—even for high-income professionals like physicians.If you're searching for a roadmap to early retirement, wondering how to create time freedom without sacrificing your profession, or want to escape the rat race through smart financial decisions, this interview gives you answers and insights. Chris's experience bridges the gap between ambition and action, offering solutions that align with what freedom-seekers are looking for in today's economy.

Remember when we used to use stacked shocks for ventricular arrhythmias or load patients up with high doses of epinephrine and bicarb? Over the last 25 years, resuscitation guidelines have evolved and it's our job to stay updated on the current protocols.Here to help us break down what's changed and what still works is Dr. Ashish Panchal, Chair of Emergency Cardiovascular Care for the AHA and host of the In the Heart of Care podcast. We discuss how a common cardiac arrest scenario would be treated from 2000 to today, highlighting key guideline changes like the shift to neuroprotective strategies, high-quality CPR, and post-arrest care.Tune in to stay current and hear how science continues to shape the way we save lives!Topics discussed in this episode:How AHA guidelines are developedDr. Panchal's research and impactEarly 2000s resuscitation guidelines“Save the brain” approach in the 2010sHow medication use has evolved, like epinephrineThe current focus on high-performance CPR and neuroprotective strategiesPost-arrest care and survivorshipBalancing clinical trends with scientific validationHow nurses can stay current on AHA guidelinesCheck out the In the Heart of Care Podcast here:https://rqipartners.com/podcast/Mentioned in this episode:CONNECT